Target intelligence / Profile preview

Ribosomal protein L23 pseudogene 11 (RPL23P11)

Target
RPL23P11
Molecular classification
Other (Pseudogene)
01

Overview

Ribosomal protein L23 pseudogene 11 (RPL23P11) is classified as a processed pseudogene related to the functional RPL23 gene, which encodes a component of the 60S subunit of the ribosome[1][5]. Pseudogenes like RPL23P11 do not code for functional proteins and are typically the result of gene duplication or retrotransposition events; they often retain sequence similarity to their parent gene but are generally considered nonfunctional in terms of protein synthesis[5].\nThere is no evidence that RPL23P11 encodes an active protein or functions as a receptor, enzyme, transporter, or other classical drug target[5].\nWhile some ribosomal protein pseudogenes have been studied for possible roles as regulatory noncoding RNAs, including effects on gene expression in cancer, this is not established for RPL23P11[2]. Thus, RPL23P11 is not recognized as a therapeutic target or biomarker, and its biological or pharmacological relevance remains uncharacterized.\nNote:\nThis query was likely intended for a real gene or protein target (such as functional RPL23), but RPL23P11 is instead a non-coding pseudogene. Entries like RPL23P11 are not generally considered drug discovery targets or actionable biological entities[1][5].

Other names
RPL23_6_1032RPL23P11
02

Mechanism of action

None

03

Biological functions

None (as a pseudogene, it does not code for protein or have a canonical biological function)
04

Disease associations

None established for RPL23P11 specifically
05

Safety considerations

None known
06

Biomarkers

None established

Beyond the preview

Go deeper on Ribosomal protein L23 pseudogene 11 (RPL23P11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L23 pseudogene 11 (RPL23P11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call